PharmTech Drug Digest 11.20
News|Articles|November 17, 2026

Neladalkib Accelerated Approval: What ALK Drug Developers Should Know

Listen
0:00 / 0:00

Key Takeaways

  • FDA accelerated approval covers post-alectinib-only patients and those receiving ≥2 prior ALK TKIs plus platinum chemotherapy, supported by Breakthrough Therapy and Orphan Drug designations.
  • ALKOVE-1 demonstrated 49% ORR after alectinib-only and 32% ORR after multiple TKIs/chemotherapy, with roughly half of responders maintaining benefit at 12 months.
SHOW MORE

The FDA grants accelerated approval to neladalkib for pretreated ALK-positive lung cancer, showing how next-gen kinase inhibitors tackle drug resistance

The FDA has granted accelerated approval to Nelkarmi (neladalkib), an anaplastic lymphoma kinase (ALK)-selective tyrosine kinase inhibitor (TKI), for adults with locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC) who have previously received either alectinib as their only prior ALK TKI, or 2 or more prior ALK TKIs and platinum-based chemotherapy.1 The decision came ahead of the original Nov. 27, 2026, target action date and follows Breakthrough Therapy and Orphan Drug designations.

Nelkarmi and Jideytro (zidesamtinib), approved in July for previously treated ROS1-positive NSCLC, both came to GSK through its $10.6 billion acquisition of Nuvalent.2

“Nelkarmi is our second new medicine approved in lung cancer this year. It was designed to help address key challenges of ALK-positive non–small cell lung cancer through its broad coverage of ALK resistance mutations, ability to cross the blood-brain barrier and high target selectivity. ALK-positive patients are often younger and can remain on treatment for years, making effective and tolerable new treatment options especially important, and we are pleased to bring this innovation to patients in the US,” said Tony Wood, CSO, GSK, in a press release.1

What Did the ALKOVE-1 Data Show?

The approval rests on the global, single-arm phase 1/2 ALKOVE-1 trial (NCT05384626).1 Its primary efficacy analysis included 222 previously treated patients with NSCLC. Among patients whose only prior ALK TKI was alectinib, the confirmed overall response rate was 49% (33 of 67). Of those responders, 76% maintained a response for at least 6 months and 52% for at least 12 months. In patients who had received 2 or more prior ALK TKIs and chemotherapy, the response rate was 32% (50 of 155), and 69% and 51% of responders reached those same durability thresholds.

In patients with measurable brain metastases at baseline, intracranial response rates were 55% in the alectinib-only group and 26% in the more heavily pretreated group.1 Complete responses made up 25% and 11% of those groups, respectively.

The most common adverse reactions, occurring in at least 20% of patients, were hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, and fatigue.1 Permanent discontinuation due to adverse reactions occurred in 5% of patients, most often because of hepatotoxicity.

“Patients with ALK-positive lung cancer are often treated with multiple targeted therapies over many years. Advances in treatment have brought us closer to the goal of managing ALK-positive lung cancer as a chronic condition, but balancing disease control and long-term tolerability remains a significant challenge. The approval of neladalkib provides an important new treatment option for patients,” said Alice Shaw, MD, PhD, an ALKOVE-1 trial investigator and chair of the Department of Medical Oncology, Dana-Farber Cancer Institute, in the press release.1

How Was Neladalkib Engineered to Overcome Earlier ALK Inhibitors’ Limitations?

Neladalkib is a macrocyclic small molecule built with minimal bulk in the kinase’s solvent-front region.3 That region is where the G1202R mutation, the most common resistance mutation after second-generation ALK TKI therapy, is thought to block binding of earlier inhibitors. Lorlatinib’s neurologic effects have been attributed to inhibition of tropomyosin receptor kinase (TRK). To spare TRK, the developers added an N-ethylpyrazole group that clashes with a larger tyrosine residue found in TRK but not in ALK. The molecule’s smaller topological polar surface area compared with lorlatinib (84 Ų vs 110 Ų) also predicted favorable brain penetrance.

Why Does This Approval Matter for Drug Developers?

As with Jideytro, Nelkarmi reflects a similar strategy: engineering newer kinase inhibitors from the outset to address the failure modes of earlier drugs in the same class.3,4 Here, those failure modes are resistance mutations, brain metastases, and toxicity that limits long-term use.

GSK describes a treatment course that can last for years, and that has implications for the supply.1A therapy patients may take for years requires sustained, predictable commercial supply.

Neladalkib is also being evaluated in other solid tumors and in ALKAZAR, an ongoing phase 3 trial in TKI-naive ALK-positive NSCLC.1

References

  1. GSK. Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non–small cell lung cancer. News release. November 17, 2026. Accessed November 17, 2026. https://www.gsk.com/en-gb/media/press-releases/nelkarmi-neladalkib-approved-in-the-us-for-previously-treated-advanced-alk-positive-non-small-cell-lung-cancer/
  2. GSK. GSK enters agreement to acquire Nuvalent, inc. News Release. June 9, 2026. Accessed November 17, 2026. https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-nuvalent-inc
  3. Lin JJ, Horan JC, Tangpeerachaikul A, et al. NVL-655 is a selective and brain-penetrant inhibitor of diverse ALK-mutant oncoproteins, including lorlatinib-resistant compound mutations. Cancer Discov. 2024;14(12):2367-2386. doi:10.1158/2159-8290.CD-24-0231
  4. Zubulake Z. What Jideytro’s approval means for drug developers. Pharmaceutical Technology. July 23, 2026. Accessed November 17, 2026. https://www.pharmtech.com/view/what-jideytro-s-approval-means-for-drug-developers

Related to this article